Trial
NCT03099265
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
—
Condition
Pancreatic Cancer
Intervention
neoadjuvant mFOLFIRINOX
Why stopped
Paused due to COVID. A determination was made to stop the study because it would be impossible to reach the 65% resection rate as outlined in the protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-27